GLP-1 Response in Women With PCOS and Prediabetes

Reduced GLP-1 Response is Associated With Prediabetes in Women With Adverse Metabolic Phenotype of PCOS Independently of BMI

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03325569

Enrollment

Registered

2017-10-30

Start date

2017-02-13

Completion date

2017-03-27

Last updated

2017-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incretin Hormones in PCOS With Prediabetes

Brief summary

Women with PCOS are more prone to obesity which exacerbates insulin resistance, the abdominal fat disposition and metabolic risk of these patients. With development of obesity these women have high conversion rate from normal glucose tolerance to impaired glucose tolerance and in turn to type 2 diabetes. Glucagon-like peptide 1 (GLP-1) is involved in body weight maintenance. Beside energy balance it is also involved in glucose homeostasis. Functional deficit in GLP-1 facilitates obesity. We investigated the link between the concentration of incretin hormones and glucose homeostasis, metabolic complications and the distribution of body composition in obese women with PCOS.

Interventions

DIAGNOSTIC_TESToral glucose tolerance test

GLP1 response to oral glucose load during oral glucose tolerance test was assessed.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* 18 years old to menopause * polycystic ovary sindrome (NICHD criteria) * BMI of 30 kg/m2 or higher

Exclusion criteria

* type 1 or type 2 diabetes mellitus * Cushing's syndrome or congenital (non-classic) adrenal hyperplasia * personal or family history of MEN 2 * the use of medications known or suspected to affect reproductive or metabolic functions * the use of statins within 90 days prior to study entery

Design outcomes

Primary

Measure	Time frame	Description
The main outcome was difference in fasting and after load GLP1 levels between two groups	3h	Patient GLP1 levels were measured at base point and in 120 min of 75-g OGTT. GLP1 levels were compared between groups

Secondary

Measure	Time frame	Description
The secondary outcome was to evaluate the between group difference in beta cell function, and visceral adipose tissue.	3h	At base point visceral adipose tissue (VAT) mass, volume and area were measured with DXA. To assess beta cell function static and dynamic parameters of beta cell function were calculated.

Countries

Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026